The biologicals regulatory situation in the EU remains murky at best. Executives share their position on the matter.
Increased prices of raw materials have strongly impacted biostimulants production. Executives share how they’ve approached this issue.
Biologicals have made big gains in row crops in Brazil. Experts weigh in on what it will take to see a similar trend elsewhere.
Experts share what the most important factors are in successfully scaling a biological company and why some businesses fail.
After 2023 saw a number of large M&A deals, experts share whether that will continue in 2024 or start to decline.
With dramatically lower farm income reported in 2023, experts share their thoughts on how growers will invest in biologicals in 2024.